Biolase (BIOL) Misses Q4 EPS by 62c

Biolase (NASDAQ: BIOL) reported Q4 EPS of ($1.28), $0.62 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $14.1 million versus the consensus estimate of $13.58 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• Alphabet stock surges 11% to record high on Q1 earnings beat, first-ever dividend
• Snap shares surge 26% on earnings beat, optimistic outlook
• Avantor (AVTR) Tops Q1 EPS by 2c